Table 1 Baseline patient characteristics
Characteristic | N =54 (%) |
|---|---|
Male (n, %) | 45 (83.3) |
Age, years, median (range) | 57.5 (27–72) |
ECOG performance | |
0–1 | 54 (100) |
Tumour differentiation | |
Well differentiated | 2 (3.7) |
Moderately differentiated | 27 (50.0) |
Poorly differentiated | 20 (37.0) |
Signet ring cell cancer | 5 (9.3) |
Site of metastasis | |
Liver | 27 (50.0) |
Peritoneum | 12 (22.2) |
Abdominal lymph node | 40 (74.1) |
Ovary | 3 (5.6) |
Bone | 1 (1.9) |
Lung | 2 (3.7) |
Left supraclavicular lymph node | 4 (7.4) |
Othersa | 2 (3.7) |
Prior gastrectomy | 23 (42.6) |
Adjuvant chemotherapy | 15 (27.7) |
Prior chemotherapy | |
Fluoropyrimidine | 52 (100) |
Platinum | 52 (100) |
Docetaxel | 19 (35.2) |
Irinotecan | 2 (3.7) |
